A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile

Microbiology (United Kingdom)

Volumn 159, Issue PART7, 2013, Pages 1254-1266

  Donald, Robert G K ^a   Flint, Mike ^b   Kalyan, Narender ^a   Johnson, Erik ^a   Witko, Susan E ^a   Kotash, Cheryl ^a   Zhao, Ping ^a   Megati, Shakuntala ^a   Yurgelonis, Irina ^a   Lee, Phillip Kwok ^a   Matsuka, Yury V ^a   Severina, Elena ^a   Deatly, Anne ^a   Sidhu, Mini ^a   Jansen, Kathrin U ^a   Minton, Nigel P ^c   Anderson, Annaliesa S ^a  

^a Pfizervaccine Research   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; BACTERIUM LYSATE; CHLORAMPHENICOL ACETYLTRANSFERASE; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; CLOSTRIDIUM DIFFICILE TOXOID A; CLOSTRIDIUM DIFFICILE TOXOID B; GLUCOSYLTRANSFERASE; RECOMBINANT VACCINE; TOXIN ANTIBODY; TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL VIRULENCE; CELL SWELLING; CHANNEL GATING; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DNA MODIFICATION; GENE EXPRESSION; GLYCOSYLATION; HAMSTER; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; INFECTION CONTROL; MUTAGENESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PURIFICATION; RECOMBINANT PLASMID;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL TOXINS; BACTERIAL VACCINES; CELL LINE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CRICETINAE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; HUMANS; MUTATION; TOXOIDS; VACCINES, SYNTHETIC;

CLOSTRIDIUM DIFFICILE; CRICETINAE;

EID: 84879819430     PISSN: 13500872     EISSN: 14652080     Source Type: Journal    
DOI: 10.1099/mic.0.066712-0     Document Type: Article

References (40)

1. Antunes, A., Camiade, E., Monot, M., Courtois, E., Barbut, F., Sernova, N. V., Rodionov, D. A., Martin-Verstraete, I. & Dupuy, B. (2012). Global transcriptional control by glucose and carbon regulator CcpA in Clostridium difficile. Nucleic Acids Res 40, 10701-10718.
2. Barth, H., Pfeifer, G., Hofmann, F., Maier, E., Benz, R. & Aktories, K. (2001). Low pH-induced formation of ion channels by Clostridium difficile toxin B in target cells. J Biol Chem 276, 10670-10676.
3. Braun, V., Hundsberger, T., Leukel, P., Sauerborn, M. & von Eichel-Streiber, C. (1996). Definition of the single integration site of the pathogenicity locus in Clostridium difficile. Gene 181, 29-38.
4. Busch, C., Hofmann, F., Selzer, J., Munro, S., Jeckel, D. & Aktories, K. (1998). A common motif of eukaryotic glycosyltransferases is essential for the enzyme activity of large clostridial cytotoxins. J Biol Chem 273, 19566-19572.
5. Chumbler, N. M., Farrow, M. A., Lapierre, L. A., Franklin, J. L., Haslam, D., Goldenring, J. R. & Lacy, D. B. (2012). Clostridium difficile Toxin B causes epithelial cell necrosis through an autoprocessing-independent mechanism. PLoS Pathog 8, e1003072.
6. Dineen, S. S., Villapakkam, A. C., Nordman, J. T. & Sonenshein, A. L. (2007). Repression of Clostridium difficile toxin gene expression by CodY. Mol Microbiol 66, 206-219.
7. Egerer, M., Giesemann, T., Jank, T., Satchell, K. J. F. & Aktories, K. (2007). Auto-catalytic cleavage of Clostridium difficile toxins A and B depends on cysteine protease activity. J Biol Chem 282, 25314-25321.
8. Fang, A., Gerson, D. F. & Demain, A. L. (2009). Production of Clostridium difficile toxin in a medium totally free of both animal and dairy proteins or digests. Proc Natl Acad Sci U S A 106, 13225-13229.
9. Genisyuerek, S., Papatheodorou, P., Guttenberg, G., Schubert, R., Benz, R. & Aktories, K. (2011). Structural determinants for membrane insertion, pore formation and translocation of Clostridium difficile toxin B. Mol Microbiol 79, 1643-1654.
10. Gerhard, R., Nottrott, S., Schoentaube, J., Tatge, H., Olling, A. & Just, I. (2008). Glucosylation of Rho GTPases by Clostridium difficile toxin A triggers apoptosis in intestinal epithelial cells. J Med Microbiol 57, 765-770.
11. Giesemann, T., Jank, T., Gerhard, R., Maier, E., Just, I., Benz, R. & Aktories, K. (2006). Cholesterol-dependent pore formation of Clostridium difficile toxin A. J Biol Chem 281, 10808-10815.
12. Gonçalves, C., Decré, D., Barbut, F., Burghoffer, B. & Petit, J.-C. (2004). Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol 42, 1933-1939.
13. Govind, R. & Dupuy, B. (2012). Secretion of Clostridium difficile toxins A and B requires the holin-like protein TcdE. PLoS Pathog 8, e1002727.
14. Heap, J. T., Pennington, O. J., Cartman, S. T., Carter, G. P. & Minton, N. P. (2007). The ClosTron: a universal gene knock-out system for the genus Clostridium. J Microbiol Methods 70, 452-464.
15. Heap, J. T., Pennington, O. J., Cartman, S. T. & Minton, N. P. (2009). A modular system for Clostridium shuttle plasmids. J Microbiol Methods 78, 79-85.
16. Heap, J. T., Cartman, S. T., Kuehne, S. A., Cooksley, C. & Minton, N. P. (2010). ClosTron-targeted mutagenesis. Methods Mol Biol 646, 165-182.
17. Hussain, H. A., Roberts, A. P. & Mullany, P. (2005). Generation of an erythromycin-sensitive derivative of Clostridium difficile strain 630 (630Derm) and demonstration that the conjugative transposon Tn916DE enters the genome of this strain at multiple sites. J Med Microbiol 54, 137-141.
18. Jank, T. & Aktories, K. (2008). Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol 16, 222-229.
19. Jank, T., Giesemann, T. & Aktories, K. (2007a). Rho-glucosylating Clostridium difficile toxins A and B: new insights into structure and function. Glycobiology 17, 15R-22R.
20. Jank, T., Giesemann, T. & Aktories, K. (2007b). Clostridium difficile glucosyltransferase toxin B-essential amino acids for substrate binding. J Biol Chem 282, 35222-35231.
21. Ke, N., Wang, X., Xu, X. & Abassi, Y. A. (2011). The xCELLigence system for real-time and label-free monitoring of cell viability. Methods Mol Biol 740, 33-43.
22. Kuehne, S. A., Cartman, S. T., Heap, J. T., Kelly, M. L., Cockayne, A. & Minton, N. P. (2010). The role of toxin A and toxin B in Clostridium difficile infection. Nature 467, 711-713.
23. Li, S., Shi, L., Yang, Z. & Feng, H. (2013). Cytotoxicity of Clostridium difficile toxin B does not require cysteine protease-mediated autocleavage and release of the glucosyltransferase domain into the host cell cytosol. Pathog Dis 67, 11-18.
24. Libby, J. M., Jortner, B. S. & Wilkins, T. D. (1982). Effects of the two toxins of Clostridium difficile in antibiotic-associated cecitis in hamsters. Infect Immun 36, 822-829.
25. Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., Shue, Y. K. & OPT-80-003 Clinical Study Group (2011). Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364, 422-431.
26. Lowy, I., Molrine, D. C., Leav, B. A., Blair, B. M., Baxter, R., Gerding, D. N., Nichol, G., Thomas, W. D., Jr, Leney, M. & other authors (2010). Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362, 197-205.
27. Lyerly, D. M., Saum, K. E., MacDonald, D. K. & Wilkins, T. D. (1985). Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 47, 349-352.
28. Reineke, J., Tenzer, S., Rupnik, M., Koschinski, A., Hasselmayer, O., Schrattenholz, A., Schild, H. & von Eichel-Streiber, C. (2007). Autocatalytic cleavage of Clostridium difficile toxin B. Nature 446, 415-419.
29. Rupnik, M., Wilcox, M. H. & Gerding, D. N. (2009). Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7, 526-536.
30. Salcedo, J., Keates, S., Pothoulakis, C., Warny, M., Castagliuolo, I., LaMont, J. T. & Kelly, C. P. (1997). Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 41, 366-370.
31. Sambol, S. P., Merrigan, M. M., Tang, J. K., Johnson, S. & Gerding, D. N. (2002). Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 186, 1781-1789.
32. Sebaihia, M., Wren, B. W., Mullany, P., Fairweather, N. F., Minton, N., Stabler, R., Thomson, N. R., Roberts, A. P., Cerdeño-Tárraga, A. M. & other authors (2006). The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat Genet 38, 779-786.
33. Simor, A. E., Bradley, S. F., Strausbaugh, L. J., Crossley, K., Nicolle, L. E. & SHEA Long-Term-Care Committee (2002). Clostridium difficile in long-term-care facilities for the elderly. Infect Control Hosp Epidemiol 23, 696-703.
34. Sougioultzis, S., Kyne, L., Drudy, D., Keates, S., Maroo, S., Pothoulakis, C., Giannasca, P. J., Lee, C. K., Warny, M. & other authors (2005). Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128, 764-770.
35. Stephenson, K. & Lewis, R. J. (2005). Molecular insights into the initiation of sporulation in Gram-positive bacteria: new technologies for an old phenomenon. FEMS Microbiol Rev 29, 281-301.
36. Teichert, M., Tatge, H., Schoentaube, J., Just, I. & Gerhard, R. (2006). Application of mutated Clostridium difficile toxin A for determination of glucosyltransferase-dependent effects. Infect Immun 74, 6006-6010.
37. Underwood, S., Guan, S., Vijayasubhash, V., Baines, S. D., Graham, L., Lewis, R. J., Wilcox, M. H. & Stephenson, K. (2009). Characterization of the sporulation initiation pathway of Clostridium difficile and its role in toxin production. J Bacteriol 191, 7296-7305.
38. von Eichel-Streiber, C., Laufenberg-Feldmann, R., Sartingen, S., Schulze, J. & Sauerborn, M. (1992). Comparative sequence analysis of the Clostridium difficile toxins A and B. Mol Gen Genet 233, 260-268.
39. Whitman, C. B. & Czosnowski, Q. A. (2012). Fidaxomicin for the treatment of Clostridium difficile infections. Ann Pharmacother 46, 219-228.
40. Zemljic, M., Rupnik, M., Scarpa, M., Anderluh, G., Palù, G. & Castagliuolo, I. (2010). Repetitive domain of Clostridium difficile toxin B exhibits cytotoxic effects on human intestinal epithelial cells and decreases epithelial barrier function. Anaerobe 16, 527-532.